Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study on the Effects of Belatacept, Ciclosporin, and Tacrolimus on Blood Vessel Health in Kidney Transplant Patients

Verified siteRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of different treatments on patients who have undergone a kidney transplant. The study involves comparing the effects of a medication called Belatacept with a group of medications known as anticalcineurins, which include Ciclosporin and Tacrolimus. These medications are used to help manage the body's immune response after a kidney transplant, which is crucial for the success of the transplant.

The purpose of the study is to see if switching from anticalcineurins to Belatacept can improve the function of blood vessels in kidney transplant patients over a period of six months. Blood vessels are important for carrying blood throughout the body, and their ability to widen and narrow properly is a sign of good health. The study will involve regular check-ups and tests to monitor the health of the blood vessels and overall well-being of the participants.

Participants in the study will be divided into two groups. One group will continue their current treatment with anticalcineurins, while the other group will switch to Belatacept. The study will last for several months, during which time participants will receive their assigned treatment and undergo various assessments to track changes in their blood vessel function. The results will help determine if Belatacept offers any advantages over anticalcineurins in maintaining healthy blood vessels in kidney transplant patients.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, eligibility is confirmed based on specific criteria such as age, kidney transplant history, and stable renal function.

    Participants are divided into two groups: the Belatacept group and the anticalcineurin group.

  2. Step 2

    Initial assessment

    An initial assessment is conducted to establish baseline measurements. This includes evaluating the dilation of arteries and other vascular functions using ultrasound and echotracking techniques.

  3. Step 3

    Medication administration

    Participants in the Belatacept group receive the medication through IV infusion.

    Participants in the anticalcineurin group continue their current oral medication, which may include ciclosporin or tacrolimus.

  4. Step 4

    Ongoing monitoring

    Regular monitoring occurs over a 6-month period. This includes measuring changes in artery dilation, blood pressure, and other indicators of vascular health.

    Blood tests are conducted to measure concentrations of specific substances related to vascular function.

  5. Step 5

    Final assessment

    At the end of the 6-month period, a final assessment is performed. This includes repeating the initial tests to compare changes in vascular function.

    The results are analyzed to determine the effects of Belatacept compared to anticalcineurins.

Who can join the trial?

7 criteria

  • For the Belatacept group: Patients who have had a kidney biopsy due to worsening kidney function and need to switch from anticalcineurins to Belatacept.
  • For the anticalcinurin group: Kidney transplant patients who have been on anticalcineurins for more than a year.
  • For the anticalcinurin group: Patients with stable kidney function, meaning their creatinine level (a waste product measured in the blood) has been steady for 3 months with only small changes.
  • For both groups: The kidney transplant must have been done more than 1 year ago.
  • For both groups: Patients must be between 18 and 75 years old.
  • For both groups: Patients must have received clear information about the study, read and understood the information letter, and signed the consent form.
  • For both groups: Women must use contraception and have a negative pregnancy test or have not had a menstrual period for 12 months.

Who cannot join the trial?

1 criterion

  • Patients who have had a kidney transplant cannot participate. A kidney transplant is a surgery to place a healthy kidney from a donor into a person whose kidneys no longer function properly.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Belatacept

    is a medication used in kidney transplant patients to help prevent the body from rejecting the new organ. It works by blocking certain signals in the immune system that can lead to organ rejection. In this trial, Belatacept is being studied to see if it can improve the function of blood vessels in kidney transplant patients.

  • Anticalcineurins

    are a group of medications commonly used to prevent organ rejection in transplant patients. They work by suppressing the immune system to stop it from attacking the transplanted organ. This trial is comparing the effects of Anticalcineurins with Belatacept to see which is more effective in improving blood vessel function in kidney transplant patients.

What is already known about the treatment

Belatacept – This medication is administered intravenously and is currently being studied for its effects on kidney transplant patients. It is used to prevent organ rejection in these patients. Belatacept works by blocking a specific signal that is necessary for the activation of T-cells, which are part of the immune system. This action helps to prevent the immune system from attacking the transplanted kidney. It is classified as an immunosuppressant.

Investigated diseases

Kidney Transplant – A kidney transplant is a surgical procedure in which a healthy kidney from a donor is placed into a person whose kidneys no longer function properly. This condition arises when the kidneys are unable to filter waste from the blood effectively, leading to a buildup of harmful substances in the body. The transplanted kidney takes over the work of the failed kidneys, allowing the recipient to lead a more normal life. Over time, the body may attempt to reject the new kidney, which is why patients often require medications to suppress the immune response. The success of a kidney transplant can be influenced by various factors, including the match between donor and recipient and the recipient's overall health. Regular monitoring and follow-up care are essential to ensure the transplanted kidney functions well.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2024-515577-10-00Protocol code2021/0391/HPEstimated enrolment44 patientsSponsorCentre Hospitalier Universitaire Rouen

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).